Our manipulative experiments to genetically correct TCF4 expression in the PTHS neural tissue provide a gateway for the development of targeted therapeutics against PTHS, as well as clinically similar diseases caused by mutations in downstream TCF4-target genes38 or even schizophrenia, which may have TCF4 as a genetic component11,13. The gene discussed is TCF4; the disease is schizophrenia.